Clinical Trials Logo

Clinical Trial Summary

To evaluate the efficacy of NYX-2925 versus placebo in treating the neuropathic pain associated with diabetic peripheral neuropathy.


Clinical Trial Description

This is a randomized, double-blind, placebo-controlled study to assess the efficacy and safety of NYX-2925 in subjects with neuropathic pain associated with diabetic peripheral neuropathy. The study will be a 13- to 16-week study, including a 1- to 4-week Screening Period, followed by a 12- week double-blind, randomized, placebo-controlled Treatment Period. ;


Study Design


Related Conditions & MeSH terms

  • Diabetic Peripheral Neuropathic Pain
  • Neuralgia
  • Peripheral Nervous System Diseases

NCT number NCT04146896
Study type Interventional
Source Aptinyx
Contact
Status Completed
Phase Phase 2
Start date November 12, 2019
Completion date February 23, 2022

See also
  Status Clinical Trial Phase
Completed NCT04094662 - A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled 14-week Study of DS-5565 in Chinese Patients With Diabetic Peripheral Neuropathic Pain Phase 3
Not yet recruiting NCT06054087 - Effectiveness of Electroacupuncture in the Treatment of Diabetic Peripheral Neuropathy N/A
Not yet recruiting NCT05292066 - Efficacy of Pregabalin Vs Duloxetine in Diabetic Peripheral Neuropathic Pain at Variable Dose Early Phase 1
Completed NCT04688671 - Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain Phase 2
Recruiting NCT06203002 - A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP) Phase 2
Completed NCT05620576 - A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05) Phase 2
Recruiting NCT05521737 - Effect of Electroacupuncture on Sensitive Symptoms of Distal Diabetic Peripheral Neuropathy N/A
Terminated NCT04707157 - Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic Pain Phase 2
Terminated NCT02156336 - Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP) Phase 4
Recruiting NCT06122012 - To Evaluate the Efficacy and Safety of HSK16149 With L-carnitine in Diabetic Peripheral Neuralgia Patients in China N/A
Recruiting NCT06221241 - Evaluate the Efficacy and Safety of JMKX000623 in Participants With Diabetic Peripheral Neuropathic Pain Phase 2
Completed NCT01314222 - Diabetic Peripheral Neuropathic Pain (DPNP) Phase 2
Completed NCT00829387 - Cognitive Behavioral Therapy for Diabetic Neuropathic Pain N/A
Not yet recruiting NCT05766969 - Diabetic Neuropathic Pain Relief, 6 Weeks Dosage Sublingual Water-soluble CBD/PEA Phase 1/Phase 2
Completed NCT05349357 - Slider Versus Tensioner Neural Mobilization in Diabetic Peripheral Neuropathy N/A
Completed NCT03909841 - Neuropathic Pain in Elderly People With Diabetes: Impact on Quality of Life and Cognition
Completed NCT04476108 - Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Diabetic Peripheral Neuropathic Pain Phase 2
Not yet recruiting NCT04953221 - The Effect of YJ001 on Diabetic Peripheral Neuropathic Pain.
Completed NCT05177094 - Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic Pain Phase 2
Completed NCT02318706 - DS-5565 Phase III Study for Diabetic Peripheral Neuropathic Pain Phase 3